Loading…
Medicaid Generic Drug Price Fairness Act
Legislative Progress
Introduced
November 20, 2014
Latest Action
November 20, 2014
Primary Sponsor
Bernard SandersIndependent(VT)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,002 other S bills in the 113th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (8)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2016 · fourth_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA. Issues related to Opioids. Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues). H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015. Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids. S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market. H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016. S.524 - To authorize the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES
2016 · fourth_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA Issues related to Opioids Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues) H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641 Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market HR 5046/S 524 - Opioid abuse legislation H.R.4641 - To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Client expense: $410,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; House 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; and HR 5046/S 524 - Opioid abuse legislation.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA Issues related to Opioids Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues) H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641 Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market HR 5046/S 524 - Opioid abuse legislation H.R.4641 - To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA. Issues related to Opioids. Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues). H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015. Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids. S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market. H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016. S.524 - To authorize the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES
2016 · third_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $290,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; House 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; and HR 5046/S 524 - Opioid abuse legislation.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $790,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA Issues related to Opioids Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues) H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641 Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market HR 5046/S 524 - Opioid abuse legislation
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA. Issues related to Opioids. Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues). H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015. Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids. S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market. H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016. S.524 - To authorize the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES
2016 · second_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market; H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 .
Client expense: $260,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA. Issues related to Opioids. Issues relating to Medicare Part D rebates. Compounding and drug supply chain legislation. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues). H.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015. Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids. S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES
2016 · first_quarter · Health Issues
Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to the FDA Issues related to Opioids Issues relating to Medicare Part D rebates. House 21st Century Cures bill (Senate companion which includes NIH and FDA issues) H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to the labeling of generic drugs. Issues relating to CDC guidance for prescribing opioids S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to removal of FDA unapproved products from the market S. 524 the Comprehensive Addiction and Recovery Act and related legislation H.R. 4641.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $470,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $240,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; issues relating to incentives for tamper-resistant formulations; issues relating to Medicare Part D rebates; compounding and drug supply chain legislation; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H. Res. 106.
Client expense: $260,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
S 2948 Medicaid Generic Drug Price Fainess Act H.R.1353 PATIENT Act of 2015 Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse FDA proposed rule on generic drug labels
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Medicare/Medicaid
issues relating to Medicare and Medicaid; Medicaid Generic Drug Pricing Fairness Act H.R.5784, S.2948
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Lobbied on issues related to abuse deterrent formulation of drugs &prescription drug abuse. FDA proposed rule on generic drug labels S. 2948 Medicaid Generic Drug Price Fairness Act Lobbied on a policy related to incentives for New Therapeutic Entities
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
H.R. 5748 and S. 2948 - The Medicaid Generic Drug Price Fairness Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
Medicare Part D Program and Generic Drugs, H.R. 5748 Medicaid Generic Drug Price Fairness Act, S. 2948 Medicaid Generic Drug Price Fairness Act
Client expense: $750,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · fourth_quarter · Medicare/Medicaid
H.R. 5748 and S. 2948 - The Medicaid Generic Drug Price Fairness Act; Issues relating to generic drug use in the Medicare Part D program
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
FDA proposed rule, Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; Federal policy relating to issues affecting the generic drug industry within the House Energy and Commerce Committee's 21st Century Cures initiative; Federal policy relating to International Nonproprietary Names for Biosimilars; HR 5657, the Fair Access for Safe and Effective Generics Act, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; HR 5748/S 2948, the Medicaid Generic Drug Fairness Act, provisions relating to Medicaid rebates for generic pharmaceuticals; Federal policy relating to the use of generic drugs in the Medicare Part D program; Federal policy relating to the implementation of the Biologic Price Competition and Innovation Act, Title VII, Subtitle A, of Public Law 111-148, the Patient Protection and Affordable Care Act; and HR 3116, the MODDERN Cures Act, provisions relating to the exclusivity term for dormant therapies
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Medicare/Medicaid
issues relating to Medicare and Medicaid; Medicaid Generic Drug Pricing Fairness Act H.R.5784, S.2948
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE